首页 | 本学科首页   官方微博 | 高级检索  
     

2剂赛尼哌预防肾移植术后急性排斥反应的应用研究
引用本文:冯新顺,薛武军,田普训. 2剂赛尼哌预防肾移植术后急性排斥反应的应用研究[J]. 中国现代医学杂志, 2002, 12(19): 7-9
作者姓名:冯新顺  薛武军  田普训
作者单位:西安交通大学第一医院肾移植科,710061
摘    要:目的 :探讨赛尼哌在预防同种肾异体移植术后急性排斥反应的作用。方法 :回顾分析了已随访 1年的 32例应用 2剂赛尼哌患者的临床效果 ,并以同期肾移植 92例作为对照组。结果 :赛尼哌组在 3月内急性排斥反应发生率 (3.1% )显著低于对照组 (2 3.9% ) (P <0 .0 5 ) ,在感染及副作用方面与对照组无显著性差异。结论 :2剂赛尼哌加上CsA ,MMP ,Pred联合应用的免疫抑制方案对预防同种尸体肾移植受者的急性排斥反应的发生是安全有效的。

关 键 词:肾移植  赛尼哌  急性排斥反应
修稿时间:2002-04-23

TWO DOSES REGIMEN OF DACLIZUMAB IN THE PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION
Feng Xinshun,Xue Wujun,Tian Puxun. TWO DOSES REGIMEN OF DACLIZUMAB IN THE PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION[J]. China Journal of Modern Medicine, 2002, 12(19): 7-9
Authors:Feng Xinshun  Xue Wujun  Tian Puxun
Affiliation:Feng Xinshun,Xue Wujun,Tian Puxun Department of Kidney Transplantation,First Affiliated Hospital of Xi'an JiaoTong University,Xi'an 710061
Abstract:Objective:To investigate its use in daclizumab in the prevention of acute rejection in renal transplant recipients.Methods:This was a non-randomized and retrospective study. A total of 32 renal transplant recipients were studied and followed. A simultaneous cohort of 92 renal transplant recipients served as control group.Results:All the patients received a follow-up of 12 months at least. Acute rejection rates were lower in the daclizumab group(3.1%) as compared to the control group(23.9%) within 3 months( P <0.05). No difference in infection episodes and adverse events between daclizumab group and control group.Conclusion:The treatment consisting of daclizumab, MMF, CsA and Pred was effective in the prevention of acute rejection in renal transplant recipients.
Keywords:Kidney Transplantation  Daclizumab  Acute Rejection
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号